SQZ Biotechnologies Company
SQZB
Other OTC0.02
USD
- -
- -
CIK
0001604477
ISIN
US78472W1045
CUSIP
78472W104
Return %
Stock
S&P500
1Y
-14.29
26.53
3Y
-95.89
76.60
5Y
-99.82
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Lawrence J. Knopf
- Full Time Employees
- 53
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 200 Arsenal Yards Boulevard Watertown MA United States of America 02472
- IPO Date
- Oct 30, 2020
- CIK
- 0001604477
- Website
- sqzbiotech.com
- Similar Companies
- Business
- SQZ Biotechnologies Company SQZ Biotechnologies Company (SQZB) operates as a clinical-stage biotechnology entity focused on cell therapies for cancer, autoimmune disorders, infectious diseases, and other serious conditions, utilizing proprietary Cell Squeeze technology for intracellular delivery via membrane disruption into various cell types including red blood cells, peripheral blood mononuclear cells, hematopoietic stem cells, T cells, NK cells, monocytes, and B cells; its platforms encompass SQZ Enhanced APC (eAPC) for tumor-specific CD8+ T cell activation, SQZ Activating Antigen Carriers (AAC) such as SQZ-AAC-HPV and SQZ-PBMC-HPV in Phase I trials for HPV16+ solid tumors like cervical, head-and-neck, anal, penile, vulvar, and vaginal cancers often combined with immuno-oncology agents, and SQZ Tolerizing Antigen Carriers (TAC) for inducing immune tolerance in autoimmune applications such as celiac disease. Founded in 2013 and headquartered in Watertown, Massachusetts, the company targets oncology, immunology, and infectious disease markets primarily in the United States with global research applicability. In a major strategic shift, SQZ sold substantially all assets—including over 400 patents, trademarks, intellectual property, proprietary equipment, and its MIT head license—to STEMCELL Technologies Canada Acquisitions Inc. for $11.8 million in early 2024, followed by shareholder approval of a plan of liquidation and dissolution filed on March 4, 2024, after which it maintains a minimal corporate presence via a PO Box in Wayland, Massachusetts, while directing Cell Squeeze-related inquiries to STEMCELL's licensing team.
STEMCELL Technologies Announces Successful Asset Purchase Agreement with SQZ Biotechnologies Company
Asset Sale and Plan of Liquidation and Dissolution Approved by SQZB Shareholders
SQZ Biotechnologies Reports Third Quarter 2023 Financial Results and Recent Portfolio Updates
SQZ Biotechnologies Reports Data for Clinical Programs at the Society for Immunotherapy of Cancer Annual Meeting
SQZ Biotechnologies Reports Second Quarter 2023 Financial Results and Recent Portfolio Updates